Charles River Laboratories International, Inc. (NYSE:CRL) Stock Position Lifted by Professional Advisory Services Inc.

Professional Advisory Services Inc. increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 13.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 73,040 shares of the medical research company's stock after buying an additional 8,936 shares during the period. Charles River Laboratories International comprises approximately 1.9% of Professional Advisory Services Inc.'s holdings, making the stock its 29th biggest position. Professional Advisory Services Inc. owned 0.14% of Charles River Laboratories International worth $14,387,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. Czech National Bank lifted its stake in Charles River Laboratories International by 0.5% in the first quarter. Czech National Bank now owns 9,025 shares of the medical research company's stock valued at $2,445,000 after buying an additional 41 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its position in Charles River Laboratories International by 1.0% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company's stock valued at $914,000 after purchasing an additional 45 shares during the last quarter. American Trust lifted its position in Charles River Laboratories International by 5.9% in the 2nd quarter. American Trust now owns 976 shares of the medical research company's stock valued at $202,000 after purchasing an additional 54 shares during the last quarter. Tortoise Investment Management LLC boosted its stake in Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock valued at $27,000 after purchasing an additional 57 shares during the period. Finally, Dumont & Blake Investment Advisors LLC increased its stake in shares of Charles River Laboratories International by 1.4% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 4,415 shares of the medical research company's stock valued at $1,196,000 after purchasing an additional 62 shares during the period. Institutional investors own 98.91% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on CRL shares. Citigroup downgraded Charles River Laboratories International from a "neutral" rating to a "sell" rating and reduced their price objective for the stock from $215.00 to $175.00 in a research report on Tuesday, October 1st. Evercore ISI cut Charles River Laboratories International from an "outperform" rating to an "inline" rating and decreased their price target for the stock from $225.00 to $190.00 in a research note on Monday, October 7th. Baird R W cut shares of Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 8th. Bank of America lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their target price for the company from $250.00 to $215.00 in a research report on Wednesday, October 2nd. Finally, Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research report on Monday. They set a "sell" rating and a $151.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $212.23.

Charles River Laboratories International Price Performance

Shares of CRL traded down $0.01 during trading hours on Friday, hitting $197.77. 700,667 shares of the company were exchanged, compared to its average volume of 596,940. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.58 and a quick ratio of 1.21. The company has a market capitalization of $10.19 billion, a PE ratio of 23.26, a PEG ratio of 5.11 and a beta of 1.36. The firm has a fifty day simple moving average of $197.26 and a 200-day simple moving average of $214.56. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, beating analysts' consensus estimates of $2.39 by $0.41. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. As a group, sell-side analysts predict that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current year.

Charles River Laboratories International declared that its board has approved a share repurchase program on Wednesday, August 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's board believes its stock is undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).